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Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that has been associated
with aberrant microbiota. This review focuses on the recent molecular insights generated by
analysing the intestinal microbiota in subjects suffering from IBS. Special emphasis is given to
studies that compare and contrast the microbiota of healthy subjects with that of IBS patients
classified into different subgroups based on their predominant bowel pattern as defined by the
Rome criteria. The current data available from a limited number of patients do not reveal
pronounced and reproducible IBS-related deviations of entire phylogenetic or functional microbial
groups, but rather support the concept that IBS patients have alterations in the proportions of
commensals with interrelated changes in the metabolic output and overall microbial ecology. The
lack of apparent similarities in the taxonomy of microbiota in IBS patients may partially arise from
the fact that the applied molecular methods, the nature and location of IBS subjects, and the
statistical power of the studies have varied considerably. Most recent advances, especially the
finding that several uncharacterized phylotypes show non-random segregation between healthy
and IBS subjects, indicate the possibility of discovering bacteria specific for IBS. Moreover, tools
are being developed for the functional analysis of the relationship between the intestinal
microbiota and IBS. These approaches may be instrumental in the evaluation of the ecological
dysbiosis hypothesis in the gut ecosystem. Finally, we discuss the future outlook for research
avenues and candidate microbial biomarkers that may eventually be used in IBS diagnosis.
Introduction
We are colonized from birth by a complex microbiota that
affects health and disease. By far the greater part of this
microbiota resides in the gastrointestinal (GI) tract, and
can be considered as an organ within an organ (Bocci,
1992). As many of the GI tract microbes have not yet been
cultured and are only recognized based on their 16S rDNA
sequences, molecular high-throughput approaches have
been developed to study the diversity and functionality of
the thousands of phylotypes that have been predicted to be
present in the GI tract (for a full review, see Zoetendal
et al., 2008). These studies have revealed that the com-
position of the microbiota in healthy adults is highly
subject-specific and stable, indicating an individual core.
Comparative microbiota analyses between multiple healthy
subjects indicate that a limited proportion of phylotypes
are shared between individuals, forming a common core
microbiota that is assumed to be functionally redundant
(Qin et al., 2010; Tap et al., 2009; Turnbaugh et al., 2009).
Recent metagenomic sequence analysis of the GI tract
microbiota has confirmed this and defined a reference set
of over three million unique genes that vastly exceeds the
coding capacity of the human genome (Qin et al., 2010).
Insight into the microbiota of healthy subjects allows
comparisons with that of compromised subjects. In the
case of inflammatory bowel diseases (IBDs), such an
approach has uncovered significant differences in overall
diversity as well as in specific bacteria (Qin et al., 2010;
Sokol et al., 2009).
Irritable bowel syndrome (IBS) is a very common disorder
with a worldwide prevalence of 10–20% (Longstreth et al.,
2006). Even though IBS does not predispose patients to
severe illness, it profoundly affects the quality of life of its
sufferers and incurs significant economic costs due to the
need for medical consultations and work absenteeism. The
symptoms of IBS vary with the individual affected, and
include abdominal pain or discomfort, irregular bowel
movements, flatulence, and constipation or diarrhoea.
According to the Rome II criteria, IBS sufferers can be
grouped into three symptom subtypes based on the stool
form, stool frequency and defaecatory symptoms: diar-
rhoea predominant (IBS-D), constipation predominant
(IBS-C), and mixed subtype (IBS-M) with alternating
episodes of both diarrhoea and constipation (Thompson
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et al., 1999; Drossman, 2000). More recently, the Rome III
criteria, which focus on the stool form over the defaecation
frequency, have been issued (Longstreth et al., 2006). The
aetiology and pathophysiology of IBS are complex and not
well-described. The most important aberrations include
visceral hypersensitivity, abnormal gut motility and auto-
nomous nervous system dysfunction, the interactions of
which are suggested to make the bowel function susceptible
to a number of exogenous and endogenous factors, such as
the GI microbiota, diet and psychosocial factors (recently
reviewed by Karantanos et al., 2010). In addition, the
presence of low-level inflammation in the GI mucosa of
IBS patients has also been observed in several studies,
including those reported by Aerssens et al. (2008),
Chadwick et al. (2002) and Macsharry et al. (2008).
Current conceptions of the intestinal microbiota
in IBS
This review focuses on recent GI microbiota research in
IBS patients, with a special emphasis on mining the
subtype-specific findings obtained using culture-indepen-
dent methods, as the initial culture-based studies had
various limitations and have already been thoroughly
reviewed in the existing literature (Lee & Tack, 2010;
Parkes et al., 2008; Quigley, 2009; Ringel & Carroll, 2009).
Evidence for gut microbes playing a role in the pathogene-
sis of IBS is convincing and is supported by three main
lines of reasoning. (1) A cause and effect relationship has
been documented between the GI microbiota and a specific
form of IBS, post-infectious IBS (PI-IBS). Due to the lack
of any published studies addressing the microbiota in PI-
IBS patients, this IBS subtype is not discussed here but is
reviewed elsewhere (Spiller & Garsed, 2009). (2) The GI
microbiota is altered in IBS patients, as will be discussed in
detail below. (3) IBS symptoms can be improved by
treatments that target the microbiota (antibiotics, probio-
tics, prebiotics). This aspect has also been recently reviewed
(Moayyedi et al., 2010; Parkes et al., 2010; Pimentel &
Lezcano, 2007) and will not be further discussed in this
review.
The differences in the intestinal microbiota between IBS
patients and healthy controls (HCs) have mostly been
studied using faecal material, as this is the most accessible
source of the GI microbiota. For clarity and easier
comparability of the results, we first discuss the results in
which IBS patients were not subdivided according to Rome
II criteria but were compared as a single group with the
HCs. The lack of segregation occurred either because the
subtypes were not specified during the recruitment of
subjects or because all IBS samples were intentionally
analysed as one group to get an overall picture and to avoid
problems of statistical power. The temporal variation of the
GI microbiota in IBS subjects was addressed in 2005 in
IBS patients by denaturing gradient gel electrophoresis
(DGGE) complemented with sequencing of 45 partial 16S
rDNA amplicons (Ma¨tto¨ et al., 2005). The results suggested
temporal instability in IBS subjects, although this was
based on qualitative inspection of the profiles and the
patients included many that were using antibiotics.
Moreover, a trend was noted whereby some Clostridium
spp. were increased and Eubacterium spp. decreased in the
IBS patients. In addressing the degree of inter-individual
variation of the gut microbiota in IBS, a recent DGGE-
based study reported a highly significant loss of variation in
IBS patients (Codling et al., 2010). In contrast, another
DGGE study, as well as comprehensive microbiota profil-
ing with the Human Intestinal Tract Chip (HITChip),
suggested that the microbiota of IBS subjects is more
heterogeneous than that of HCs (Rajilic´-Stojanovic´, 2007).
In conclusion, both an increase and a decrease of variation
have been proposed to characterize the GI microbiota
in IBS. From an ecological perspective, the abnormal
variation likely reflects a loss of homeostasis, in which the
community is unable to maintain its normal structure. A
high degree of variation is typical for disturbed and re-
establishing communities undergoing succession, while the
loss of variation is usually associated with a loss of diversity
and outgrowth of certain taxa.
Microbiota in different IBS subtypes
The statistically significant microbiota differences from
peer-reviewed molecular studies that have analysed IBS
subtypes separately are summarized in Table 1. Of the eight
studies listed in Table 1, five analysed samples from the
same Finnish IBS cohort with complementary methodo-
logies: qualitative microbiota profiling (Maukonen et al.,
2006; Ma¨tto¨ et al., 2005) was followed by targeted analyses
using quantitative PCR (qPCR) assays that were specific to
dominant genera and species (Malinen et al., 2005) and
phylotypes with a putative association with IBS (Lyra et al.,
2009). To obtain a holistic assessment of the entire
microbiota, 16S rDNA sequencing of clone libraries was
performed on the selected fractions of all IBS subtypes
(Kassinen et al., 2007) as well as on the entire GI
microbiota of IBS-D patients and HCs (Krogius-Kurikka
et al., 2009).
An important basis for this field was provided by the first
study that addressed the putative quantitative microbiota
differences in IBS patients by the application of qPCR
assays that covered the predominant bacteria as well as taxa
with a potential association with IBS based on culturing
(Malinen et al., 2005). To obtain an overall impression of
the GI microbiota in the patients, all IBS samples were
combined, and were found to contain fewer Clostridium
coccoides and Bifidobacterium catenulatum groups than the
HCs. Upon comparison of the three IBS subgroups with
the HCs, lactobacilli were significantly decreased in the
IBS-D compared with the IBS-C patients, who also had
significantly more Veillonella spp. than the HCs. Other
group-level assays did not show significant differences
between the subject groups; at the species level, Ruminococcus
productus–C. coccoides was significantly increased in all IBS
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subtypes compared with the HCs. A single IBS subject
harboured Campylobacter jejuni, while no other indications
of intestinal pathogens previously linked to IBS were found
(Malinen et al., 2005).
The same IBS subjects that had previously shown temporal
instability (Ma¨tto¨ et al., 2005) were readdressed by
excluding those patients who had recently received anti-
biotics (Maukonen et al., 2006). The temporal variation of
the GI microbiota was not higher in IBS patients according
to the DNA-based DGGE profiles, while faecal RNA
amplicons were more stable in the HCs. The study focused
on the dominant clostridial populations due to their
possible link to gas-related problems in IBS, and detected a
relative decrease of Clostridium cluster XIVa in IBS-C and
IBS-A samples, in line with the qPCR results of Malinen
et al. (2005).
The first study to apply extensive 16S rDNA gene cloning
and sequencing to compare the faecal microbiota of IBS
patients with that of HCs was published in 2007 (Kassinen
et al., 2007). In that study, faecal community DNA was
pooled within IBS subgroups and the HCs in order to focus
on the IBS status of subjects rather than on individual
variation. The community DNA was fractionated accord-
ing to the %G+C content to facilitate the recovery of less
abundant species and of sequences with a high G+C
content. The three most variable %G+C fractions between
the groups, representing bacterial genomes with %G+C
values of 25–30, 40–45 and 55–60, were then subjected to
cloning and sequencing. Within-fraction comparison of
the sequences showed that the libraries derived from the
three IBS subtypes and HCs were clearly distinguishable in
Bayesian population structure analysis, and multiple
statistically significant differences were found at the genus
level (Table 1; Kassinen et al., 2007). In brief, IBS-D
patients were depleted in several Firmicutes and Bacteroides
spp. in the middle %G+C region, while IBS-C patients
had elevated amounts of many of the lower G+C content
Firmicutes. Actinobacteria in the highest %G+C fraction
were depleted in all IBS subtypes compared with the HCs.
Finally, to complement and verify the sequencing data
from the pooled samples, individual samples were analysed
using a set of qPCR assays designed to target the phylotypes
that differed most between the libraries. Collinsella
aerofaciens, an abundant actinobacterium, as well as two
uncharacterized Firmicutes, Clostridium cocleatum-related
and Coprococcus eutactus-related, were significantly
decreased in all IBS subtypes compared with the HCs.
Essentially similar differences were obtained when samples
from around 30 additional IBS subjects were analysed,
suggesting a true negative association between these
phylotypes and IBS (Kassinen et al., 2007).
The same diarrhoea-predominant IBS patients were further
analysed by extending the analysis coverage from the
selected %G+C regions, which comprised one-third of the
total community DNA, to the entire microbiota. Com-
parison of the 16S rDNA clone libraries between the IBS-D
group and HCs pointed out several significant differences
(Table 1; Krogius-Kurikka et al., 2009), confirming and
extending the findings of Kassinen et al. (2007). In brief,
Lachnospira and family- or genus-level representatives of
the gammaproteobacteria and bacilli were enriched in IBS-
D, while Bacteroides and Ruminococcus spp., as well as three
genera assigned to the Actinobacteria, were depleted.
Interestingly, these taxa also stood out from clone libraries
derived from IBD patients (Frank et al., 2007), and from an
individual suffering from Clostridium difficile-associated
disease (CDAD) with severe diarrhoea and colitis (Khoruts
et al., 2010). IBD, CDAD and IBS-D patients were all
significantly depleted in sequences affiliated to
Bacteroidetes and had a concomitant enrichment of other
commensals. More specifically, proteobacteria and bacilli
were enriched in IBS-D and IBD samples, while strep-
tococci, Erysipelotrichi and Lachnospiraceae Incertae Sedis
were increased in IBS-D and CDAD patients. The
Erysipelotrichi are a Firmicute class containing only a few
named species, including the long-known animal and
human pathogen Erysipelothrix rhusiopathiae. Recently, the
increase of Erysipelotrichi has been associated with obesity
(Zhang et al., 2009) as well as high fat intake (Fleissner
et al., 2010). Another emerging taxon of interest is
the abundant and typically butyrate-producing family
Lachnospiraceae, and especially the genus Lachnospiraceae
Incertae Sedis, which has been shown to be significantly
enriched in IBS-D and CDAD but depleted in IBD patients
(Frank et al., 2007). Representatives of the Lachnospiraceae
express highly antigenic flagellins (Duck et al., 2007), which
have been recognized as triggers of elevated immune
reactivity in Crohn’s disease patients and a subset of IBS
patients (Schoepfer et al., 2008). In summary, these
findings suggest new candidate bacteria with potential
associations with the health status of the carriers, and
underline the importance of studying them in more detail.
The relevance of the diverging phylotypes identified by
sequence analysis (Kassinen et al., 2007) was addressed by
the design of phylotype-specific qPCR assays, which were
applied to IBS and HC samples with 6 months’ follow-up
(Lyra et al., 2009). Multivariate analysis of the collective
data from 14 qPCR assays showed that the IBS-D samples
differed significantly from the other sample groups,
confirming that a panel of selected bacteria can be used
to distinguish IBS subtypes from each other and from the
HCs. When the individual assays were analysed, four
uncharacterized Firmicutes phylotypes diverged signific-
antly between the different IBS subtypes and the HCs
persistently over time (Table 1). Two of the phylotypes
showed moderate similarity to Ruminococcus torques, a
mucin-degrading Clostridium.
Phylogenetic microarrays offer high-resolution and
-throughput tools to study complex microbial ecosystems
(reviewed by Zoetendal et al., 2008). Application of the
HITChip has allowed simultaneous detection and iden-
tification of over one thousand intestinal phylotypes in IBS
patients and HCs (Rajilic´-Stojanovic´, 2007). In an overall
Intestinal microbiota in IBS patients
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Table 1. Alterations in the GI microbiota composition of subtyped IBS patients
Comparisons were made among all studied IBS groups and healthy controls; statistically significant differences between at least one pair wise comparison are listed. All subjects were recruited
according to Rome II criteria. Studies marked with ¤ have used samples from the same cohort.
IBS-D IBS-C IBS-A HCs Common in IBS Method Taxonomic coverage
and resolution
Reference
Lactobacilli Q
n512
Lactobacilli q
Veillonella q
n59
n56 n522 B. catenulatum Q
C. coccoides groups Q
R. productus q
C. coccoides species q
qPCR 12 genera/groups,
8 species
Malinen et al.
(2005)¤
n57 C. coccoides–
Eubacterium
rectale group Q
n56
Temporal stability
of Clostridium
histolyticum group q
n53
n516 Temporal stability
of predominant
bacteria Q
DGGE, affinity
capture
Total bacteria
and 4 clostridial
groups
Maukonen et al.
(2006)¤
10 genera* Q
Streptococci q
n510
5 generaD Q
6 generad q
n58
5 genera§d Q
7 genera||§ q
n56
n523 Collinsella Q
Collinsella aerofaciens Q
C. cocleatum 88% Q
Coprococcus eutactus
97%Q
GC profiling+
sequencing of
16S rDNA library
qPCR
Whole community;
phylotypes
Kassinen et al.
(2007)¤
Clostridium symbiosum-likeQ
5 genus-level taxa q
n57
5 genus-level
taxa# Q
6 genus-level
taxa**q
n58
C. symbiosum Q
Prevotella oralis Q
4 genus-level
taxaDD q
n55
n520 Bacteroides spp. Q
Bacillaceae q
Microarray Whole
community;
131 genus-level
groups
Rajilic´-Stojanovic´
(2007)
n514 n511 n516 n524 Bifidobacteria Q
Clostridium
lituseburense group Q
FISH, qPCR 8 genera/groups;
4 species
Kerckhoffs et al.
(2009)
Higher richness of Firmicutes
6 generadd Q
6 genera§§ q
n510
n523 GC profiling+
sequencing of
16S rDNA library
Whole community;
phylotypes
Krogius-Kurikka
et al. (2009)¤
IBS-D most different in
multivariate analysis
R. torques 94% q
Clostridium thermosuccinogenes
85% q
n58
Ruminococcus bromii-
likeq
n58
C. thermosuccinogenes
85%q
R. torques 93%Q
n54
n515 qPCR 14 phylotypes Lyra et al. (2009)¤
n58 n511 Veillonella q
n57
n526 Lactobacilli q
Veillonella q
qPCR, culture 10 genera/groups Tana et al. (2010)
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comparison, the amount of Bacteroides spp. was signifi-
cantly decreased and the amount of bacilli increased in the
IBS patients. Separate analysis of each of the IBS subgroups
showed that IBS-D patients differed the most and IBS-C
patients the least from the HCs, although none of the
differences reached statistical significance. A compositional
analysis of samples representing all three subtypes and the
HCs revealed that a total of 19 genus-level taxa, represent-
ing Bacteroidetes, bacilli and Clostridium clusters III, IV
and XIVa, differed significantly between the groups
(Rajilic´-Stojanovic´, 2007). The amount of Bacteroides spp.
was the lowest in IBS-C patients, while IBS-D patients had
elevated amounts of streptococci. Most of the significant
differences occurred between a single IBS subtype and the
HC group, while five genera from Clostridium cluster IV
differed most between the IBS-C and IBS-D groups, the
first group having higher levels of these organisms.
Bifidobacteria and lactobacilli have been studied in many
IBS trials due to their potential association with health.
Decreased counts of bifidobacteria have been reported in
IBS patients (Kerckhoffs et al., 2009; Malinen et al., 2005),
especially of the B. catenulatum group (Kerckhoffs et al.,
2009; Lyra et al., 2009; Malinen et al., 2005). A decrease of
lactobacilli has been detected in IBS-D (Malinen et al.,
2005; Krogius-Kurikka et al., 2009) and IBS-A patients
(Kerckhoffs et al., 2009). On the other hand, untypically
high faecal amounts of lactobacilli and/or streptococci have
been reported for IBS-D patients (Kassinen et al., 2007;
Krogius-Kurikka et al., 2009; Carroll et al., 2008) as well as
IBS patients independent of the subtype (Tana et al., 2010).
This trend suggests that at least some IBS patients, similarly
to ileostomy patients, have an outgrowth of aerobic
bacteria that may be linked to the overproduction of
organic acids, as will be discussed below.
Few studies have addressed the variability and composition
of mucosa-associated GI microbiota in IBS patients. A
fluorescence in situ hybridization (FISH) study showed
unsubtyped IBS patients to harbour slightly more total
bacteria and significantly more members of Clostridium
cluster XIVa than the HCs (Swidsinski et al., 2005).
Otherwise, the amount and distribution of mucosal
bacteria were comparable with that of healthy subjects, in
contrast to the drastic quantitative and qualitative
differences detected in the IBD samples. Fingerprinting
analysis to qualitatively characterize the mucosal micro-
biota has been employed in a small number of unsubtyped
IBS patients (Codling et al., 2010) as well as in IBS-D
patients in parallel to HCs (Carroll et al., 2010). Codling
and co-workers found no significant differences in the
variability of faecal and mucosal microbiota. The study of
Carroll and co-workers found significant differences in the
mucosal but not in the faecal communities between the
patients and HCs, while the mucosal and faecal com-
munities differed significantly within a subject indepen-
dently of the health status. Not only the composition but
also the degree of diversity of the microbiota was changed
in a more pronounced manner in the mucosal samples. A*B
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qPCR analysis of subtyped IBS patients has revealed a
statistically significant decrease of B. catenulatum in the
duodenal mucosa of IBS patients independently of the
subgroup (Kerckhoffs et al., 2009). This study was limited
to selected bifidobacterial species and did not investigate
the other genera in the duodenal microbiota at all. In
summary, it is too early to conclude that the mucosal
microbiota in IBS patients differs from that in healthy
subjects. In any case, integrated studies of both mucosal
and luminal communities are relevant, because the former
directly communicates with the host while the latter vastly
dominates the metabolic output of the GI microbiota,
providing two complementary aspects to address the role
of gut bacteria in IBS.
How should the present data on IBS-related
microbiota be interpreted?
The existing literature on the GI microbiota in IBS, as
summarized in Table 1 and discussed above, does not reveal
uniform alterations in microbiota composition shared
among all patients. The in-depth analysis of a single IBS
cohort using different methodologies supports the notion
that studies that apply different analysis methods to target
bacteria with variable taxonomic resolution are difficult to
compare. Nevertheless, the results complement each other,
and together with other trials reveal some subtype-specific
microbiota features. The GI microbiota of IBS-D patients
seems to deviate the most and that of IBS-C patients the least
from that of HCs (Lyra et al., 2009; Rajilic´-Stojanovic´, 2007).
Most of the observed differences could be assigned to the
Firmicutes, as they dominate the significant alterations in
the comparison of clone libraries (Kassinen et al., 2007;
Krogius-Kurikka et al., 2009), microarray-derived micro-
biota profiles (Rajilic´-Stojanovic´, 2007) and qPCR assays
(Lyra et al., 2009; Malinen et al., 2005; Tana et al., 2010)
between IBS patients and HCs. More specifically, the genera
Streptococcus, Lactobacillus and Veillonella, as well as members
of the families Lachnospiraceae and Ruminococcaceae, stand
out from the comparisons, although with a somewhat
inconsistent association with IBS status. In particular, IBS-D
patients are frequently enriched with streptococci and show a
distinctive set of dominant Clostridia. Members of the
Bacteroidetes and Proteobacteria show some differences,
although this was not the case in several studies. Actino-
bacteria, including bifidobacteria and coriobacteria (mainly
of the genus Collinsella), contribute to the differences in
several datasets as well. The repeated appearance of the above-
mentioned taxa as significantly different between IBS patients
and HCs suggests a highly probable association of these
organisms with IBS, and warrants their further investigation
in this area of research.
In addition to the limited number of phylum- and group-
level differences, several genus- and species-level alterations
in abundance have been identified in IBS patients in studies
that achieved this taxonomic resolution (Table 1; Kassinen
et al., 2007; Krogius-Kurikka et al., 2009; Lyra et al., 2009;
Rajilic´-Stojanovic´, 2007). Most of these differences would
have remained undetected by conventional approaches that
study the higher taxonomic levels. As the evolutionary
distance of different bacterial phyla is comparable with that
of animals and plants in the rRNA-based tree of life
(Woese, 1987), the vast genetic and phenotypic hetero-
geneity of the taxa classified into a phylum makes the
phylum-wide differences unlikely. Thus, microbial analysis
on the genus or lower taxonomic level facilitates the
identification of differences that more probably reflect the
phenotypic alterations of the microbiota. However, the
phylogenetic similarity does not necessarily reflect the
functional similarity and vice versa. To exemplify, the
abundance of two uncultured phylotypes having 93 and
94% similarity to the 16S gene of R. torques differed
significantly between the clone libraries derived from
healthy and IBS-D patients, so that the former phylotype
was significantly enriched in the HCs and the latter in IBS-
D (Lyra et al., 2009). Such a polarized segregation of
related phylotypes explains the lack of uniformity at the
higher taxonomic levels and highlights the need to verify
the compositional differences with additional genetic
information whenever available. Currently, we cannot
functionally interpret most of the findings; for many of
the taxa that differ significantly there is a complete lack of
prior information or at best only moderate similarity to a
characterized member of the gut ecosystem. The limited
characterization of the GI microbiota not only challenges
the understanding of its role in health but also highlights
the diagnostic potential of its undiscovered taxonomic and
functional attributes. After all, despite the missing
information about the functional impact of the emerging
phylotypes, they still can function as valuable (bio)markers
for a particular health status.
Functional perspective on IBS-related microbiota
Beyond the above-discussed compositional differences,
some data are available on the functional impact of the
GI microbiota and its dysbiosis on the aetiology of IBS. The
investigation of IBS-related microbial functions is currently
limited to organic acids and intestinal gas, as will be
discussed below. A significant increase of bacterially pro-
duced short chain fatty acids (SCFAs) was recently
recorded in the faeces of Japanese IBS patients who also
harboured significantly more lactobacilli and Veillonella
spp. compared with HCs (Tana et al., 2010). The increase
in total SCFAs was due to the increase of acetic and
propionic, but not butyric, acid. Conceptually, this study
adds a new perspective to the IBS field, as it utilized
multiple datasets in the same cohort by simultaneously
addressing the microbiota, their metabolites and the
amount of gas produced, as well as making a subjective
evaluation of GI symptoms and quality of life. Except for
colonic gas, the parameters were found to vary non-
randomly between the patients and the HCs. In brief, the
authors hypothesize that the higher numbers of lactobacilli
and Veillonella spp. in IBS patients result in a high level of
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organic acids, which correlates with abdominal pain,
bloating, anxiety and poor quality of life. The increase
in acids was suggested to affect visceral sensation and
manifest as a low somatic and emotional score. Although
the work of Tana and co-workers is of great interest, their
conclusions should be considered with some caution,
because the central hypothesis is based solely on culture-
based enumeration of lactobacilli that resulted in untypi-
cally low values both in the patients and the HCs (mean
log10 bacterial counts of 4.6 and 5.6 per gram of faeces,
respectively). Moreover, qPCR was used to quantify 10
bacterial groups excluding lactobacilli, despite their high
relevance, further emphasizing the tentative nature of the
link between lactobacilli, SFCAs and GI symptoms.
Nevertheless, the suggested link between the SFCA profile
and GI symptoms can be discussed in the light of the
contrasting biological activities of the SFCAs. Acetate is a
known chemical irritant, and at high concentrations is used
to induce mucosal lesions and abdominal cramps in
experimental animals, while butyrate is considered as
protective and able to dose-dependently reduce abdominal
pain in humans in vivo (Vanhoutvin et al., 2009). While
IBS patients as a single group differed significantly from the
HCs with respect to organic acids and microbiota, none of
the three subtypes alone showed a significant difference in
these aspects (Tana et al., 2010). Similarly, in the study of
Malinen et al. (2005), all IBS subgroups had elevated levels
of Veillonella spp., C. coccoides and R. productus, all able to
produce acetate and succinate (Liu et al., 2008). However,
as IBS-D patients have also been documented to have more
butyrate but less total SCFAs than HCs (Treem et al.,
1996), and as butyrate induces visceral hypersensitivity in a
rat model (Bourdu et al., 2005), the clinical effects of
organic acids in IBS remain to be verified.
In addition to the acid producers, GI microbes associated
with the control of colonic gas either through its production
or disposal may be implicated in IBS through flatulence and
bloating. While all intestinal hydrogen (H2) results from
microbial fermentation, the bacteria involved and their role
in IBS are difficult to study. First, the conventional
quantification of H2 is based on breath tests of controversial
reliability, and second, the majority of gut bacteria can
produce H2. An initial study that suggested the role of H2 in
IBS analysed the total excretion of colonic gas in six IBS
patients, who showed elevated production of H2 on a fibre-
rich diet, although the total volume of gas did not differ
when compared with the HCs (King et al., 1998). Similarly,
Tana et al. (2010) found no difference in the amount of X-
ray-quantified colonic gas between the IBS patients and the
HCs. Recently, Serra et al. (2010) demonstrated that IBS
patients have sensory dysfunction and poor tolerance to
moderate gas loads, in line with the hypothesis that the IBS
symptoms arise more from the visceral hypersensitivity than
from the elevated amount of intestinal gas.
Three alternative and potentially competing microbial
groups dispose of most of the colonic H2: acetogens,
methanogenic Archaea and sulfate-reducing bacteria (SRB)
(extensively reviewed by Nakamura et al., 2010). The
removal of H2 not only effectively reduces the volume of
gas and the pressure in the gut but also regulates the
amount of acetate, a potential chemical trigger of IBS
(discussed above). The phylogenetically diverse and
numerically abundant acetogenic bacteria have not yet
been specifically addressed in any IBS cohort. Despite the
fact that methane (CH4), produced by methanogenic
Archaea, has a proven causative and mechanistically
described link to constipation (Pimentel et al., 2006), only
a few studies have studied the methanogenic Archaea in
IBS patients. Based on breath testing, both the prevalence
and the rate of CH4 production were lower in unsubtyped
IBS patients than in HCs (Rana et al., 2009). However,
direct PCR-based enumeration of methanogens found no
difference in their prevalence between the IBS and HC
groups, in contrast to the significantly lowered incidence of
these organisms in IBD patients (Scanlan et al., 2008). H2
disposal via sulfate reduction generates toxic hydrogen
sulphide (H2S), and the impact of SRB is considered
detrimental to the host. Two studies so far have studied the
amount of SRB in IBS patients. In the qPCR analysis of
Malinen et al. (2005), IBS subjects tended to harbour fewer
Desulfovibrio spp., the predominant SRB genus in the gut,
while culture- and FISH-based analysis of IBS-C subjects
showed significantly more SRB compared with HCs
(Chassard et al., 2009). While the current studies do not
provide conclusive results about the role of H2-disposing
bacteria in IBS, their involvement in the regulation of
colonic gas, transit rate and chemical stimuli associates
them strongly with GI symptomology and thereby warrants
their further research.
From an ecological perspective, any species with a relevant
trait can contribute to the disease process, assuming its
metabolic activity in a given environment. Currently, we
lack knowledge of bacterial genes associated with specific
GI symptoms. Even after identification of the relevant
microbial activities, their examination remains challenging,
as most of the ecological niches in the colonic ecosystem
are occupied by phylogenetically diverse and functionally
redundant bacteria that require targeting of key enzymes in
a given pathway instead of the conventional analyses
relying on 16S rDNA. So far, the only described gene-
specific assays putatively relevant to IBS are the ones that
target butyrate biogenesis (Louis et al., 2010) and the
different H2 disposal routes discussed above (Nakamura
et al., 2010).
Suggestions for future research
In addition to the identification of bacteria potentially
affiliated with IBS, the employment of recent high-
throughput methods has also emphasized that several
conceptual challenges prevail in the current attempts to
scrutinize the GI microbiota in IBS or indeed any other
disease. Despite the intensive attempts to define the
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parameters for a normal GI microbiota in the absence of
any detectable disease, currently we must content ourselves
with the conception that healthy subjects carry an immense
selection of different phylotypes that vary greatly in their
abundance and show little overlap between individuals.
Even at the phylum level, substantial variation can exist in
relative abundance not only between individuals but also
within individuals over time (Turnbaugh et al., 2009).
Moreover, the abundance of many bacteria varies remark-
ably, by as much as 2000-fold or more (Qin et al., 2010).
Therefore, the depth of analysis largely determines which
bacteria will be considered as present and consequently the
extent of shared bacteria (J. Jalanka-Tuovinen & W. M. de
Vos, unpublished results; Qin et al., 2010). If the sus-
ceptibility of the host has a decisive role in IBS manifes-
tation, we may expect a subset of patients to carry a
microbiota that is not substantially disturbed, further
adding to the high subject-to-subject variation among IBS
patients. Due to the low number of IBS patients analysed so
far and the high individuality of the GI microbiota, future
cohorts of sufficient size will be essential. They will be
imperative both for validating the taxa with a recently
established association with IBS and for discovering new
diagnostic species.
Focused analyses can remove some of the heterogeneity in
IBS patients. The relevance of IBS subtyping to the
microbiological analyses is highlighted by the recognition
of the large microbiota variation between the subtypes
and the consequent difficulty in extrapolating microbial
characteristics from one IBS subtype to another. For some
bacterial groups, a trend whereby the abundance gradually
descends from the IBS-C samples to the HCs and further to
the IBS-D samples (Kerckhoffs et al., 2009; Malinen et al.,
2005; Rajilic´-Stojanovic´, 2007) can be observed. This
finding suggests that addressing luminal conditions such
as transit time and pH, known to critically influence the
composition of the GI microbial community (Duncan et
al., 2009; Louis et al., 2007), would be highly relevant in
IBS and HCs, as we need to learn more about how the gut
environment and related ecological selection forces relate
to intestinal function and gut health.
Self-reported symptom diaries, routinely used to measure
possible symptom alleviation in clinical trials, should also
be employed in basic research because they allow coupling
of the microbiological parameters to the subjective feeling
of intestinal health on the day of faecal sampling. Diaries
should be collected not only from patients but also from
the HCs, as occasional digestive complaints such as
bloating and flatulence are frequent in healthy subjects as
well. Using this approach, the research findings have the
potential to expand from microbiota traits that differ
between the IBS patients and the HCs to symptom-specific
traits that are independent of the carrier’s diagnosis. Pilot
studies correlating GI symptoms with the microbiota have
recently been published (Malinen et al., 2010; Tana et al.,
2010). As discussed earlier, the work of Tana and co-
workers suggests that lactobacilli and Veillonella spp.
correlate positively with GI symptoms and impaired
quality of life. Malinen and co-workers correlated symp-
tom data with 13 different qPCR assays targeting predomi-
nant genus-/group-level taxa as well as distinct phylotypes
that were previously associated with IBS patients in
sequence analyses (Lyra et al., 2009). The major finding
was that R. torques 94%, a phylotype originally identified
as being overrepresented in an IBS-D-derived clone library
(Lyra et al., 2009), showed a strong and significant positive
correlation with various bowel symptoms in another set of
unsubtyped IBS patients. Such a finding is encouraging in
the search for putative symptom-associated bacteria that
may eventually be employed in mechanistic studies and for
diagnostic purposes.
Finally, to improve the comparability and generalization of
the outcome of different trials, the plethora of variables
arising from the non-standardized recruitment criteria,
sample processing and analysis techniques, as well as the
bioinformatic and statistical methods used for the data
analysis, should be controlled.
Outlook for microbes as biomarkers for IBS
Table 2 lists the different aspects of the GI microbiota that
are considered relevant to future research with regard to
Table 2. Future GI health biomarker candidates arising from the microbiota
The list does not aim to be exhaustive but rather gives examples of how to compare GI microbiota in patients and healthy subjects.
Conceptual target Variable to measure Reasoning
Composition Presence, absence, relative over- or underrepresentation
of specific bacteria (see text for potential candidate taxa)
Specific measurement of compositional differences
Ecology Diversity, richness, evenness, resilience Overall assessment of the ecosystem
Activity and/or
functional
dysbiosis
Metabolites, proteins, gases/acidosis, aerobiosis,
accumulation of gas, toxaemia
Measurement of the functional attributes, which can
contribute to symptoms either directly or by interfering
with normal host–microbiota mutualism
Stability Temporal variation Measurement of how the composition, ecological parameters
and activity vary within and between individuals
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intestinal health, and thus have the potential to be
employed as biomarkers for IBS and other functional
intestinal aberrations. As we currently lack the criteria to
define when a microbiota is aberrant, we believe that the
simultaneous examination of multiple aspects listed in
Table 2 will be the most fruitful and reliable approach in
determining the extent to which particular microbiota
profiles overlap between patients and differ from those of
HCs.
Due to the paucity of molecular data currently available
from IBS patients, it remains possible that specific IBS
biomarker bacteria will be discovered in future studies.
More probably, an over- or underrepresentation of certain
bacteria features in the microbiota in IBS, reflecting
compositional shifts that either precede or follow the
pathophysiological changes in the host. This field of
research is expected to capitalize on the current availability
of high-throughput sequencing and microarray technolo-
gies so that community-level surveys between IBS patients
and HCs become a standard approach. The application of
diversity and stability indexes together with other eco-
logical measures such as the degree of complexity and
evenness may provide informative measures to evaluate
overall differences between communities. At present,
stability and diversity indexes are used as descriptive
measures, as their optima and overall relevance with
respect to GI health are unclear.
As discussed above, we have limited knowledge of the
functionality of the GI microbiota in health and disease. The
first publications that utilize whole-community metage-
nomics or functional genomics (metatranscriptomics,
metaproteomics and meta-metabolomics) on IBS cohorts
are still to come. They will allow a holistic assessment of
putative IBS-specific functions in the gut microbiota and
reveal possible gene dosage differences. A recent metage-
nomic study revealed a 25% gene loss in IBD patients
compared with HCs (Qin et al., 2010), establishing a basis
for the identification of microbiota-derived functions that
are decisive for the manifestation of GI symptoms. Finally,
the initial finding of the temporal instability of IBS patient
microbiota (Ma¨tto¨ et al., 2005) should be readdressed by
repeated sampling of patients to provide a longitudinal
aspect for the structural and functional attributes of their
microbiota. A subset of healthy individuals without any
intestinal complaints appear to carry unstable GI microbiota
(Engelbrektson et al., 2009). While this may be anecdotal, it
emphasizes the need for further research to confirm the
relevance and extent of the temporal instability that possibly
characterizes the microbiota in IBS.
Current research has uncovered subtle changes rather than
dramatic alterations in the GI microbiota of IBS patients,
with considerable structural overlap with HCs. This
synopsis strongly suggests homeostasis of the microbiota
to be a critical element in the pathophysiology of IBS, in a
manner analogous to the development of dental caries
according to the proposed ecological plaque hypothesis
(Marsh, 2003). This hypothesis is based on the concept that
the presence or abundance of an individual taxon has little
clinical significance, and that the development of disease is
instead associated with community-level alterations that
reflect the breakdown of homeostasis. The existing data
strongly support the existence of the intestinal ecological
dysbiosis hypothesis, which states that multispecies signa-
tures specify the GI microbiota in a given health status such
as IBS. Consequently, community-level analyses and an
ecological perspective are needed to identify and interpret
these signatures. Understanding the metabolic co-depend-
ence between different bacteria will provide the biological
basis for understanding how a certain set of species can
contribute to disease, and consequently how to manipulate
the GI environment to restore a healthy microbiota state.
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